Wojciech Sasiadek, MD

  • Clinical Assistant Clinical Professor of Radiation Oncology
  • Physician, UPMC Whitfield Cancer Centre

I provide oversight and supervision of clinical radiation oncology at UPMC CancerCenter Ireland in Whitfield Clinic, Waterford. It includes providing service for private/public sector referred to the Whitfield Clinic as well as public patients in Waterford University Hospital in Waterford. I am involved in multiple multidisciplinary groups including: head and neck multidisciplinary team, upper/lower gastro-intestinal team, melanoma multidisciplinary team, and gynecological multidisciplinary team for southeast region of Ireland. My main research points of interest are radiobiology, combined treatment of rectal cancer, early and late toxicity of radiotherapy for head and neck and lower GI carcinomas. Due to collaboration with medical oncology/ palliative care consultants in Waterford University Hospital, I am involved in lectures for residents and medical students. I am also involved in collaboration with Waterford Institute of Technology.

Teaching Activities:

I am actively involved in collaboration with Waterford University Hospital, teaching hospital for southeast Ireland, in form of meetings/ teaching lectures for registrars, medical students, and nurses involved in cancer treatment.

Representative Publications

“Predicting Radiotherapy-Related Clinical Toxicities in Cancer: A Literature Review” Claire O’Gorman, BSc, PGDip, RGN, Wojciech Sasiadek, MD, Suzanne Denieffe, MSc, BNS, RGN, RPN, RNT, PhD, and Martina Gooney, BSc, PhD, June 2014 • Volume 18, Number 3 • Clinical Journal of Oncology Nursing

“Nursing implications: symptom presentation and quality of life in rectal cancer patients” Claire O’Gorman, Amanda Barry, Suzanne Denieffe, Wojciech Sasiadek and Martina Gooney, Journal of Clinical Nursing, doi: 10.1111/jocn.13234

Research Grants

Source/Grant Number: A Randomised Phase III Trial of Two Fractionation Schemes in the Treatment of Malignant Spinal Cord Compression

Grant Title: ICORG - A Randomised Phase III Trial of Two Fractionation Schemes in the Treatment of Malignant Spinal Cord Compression

Role in Project & Percentage of Effort: Principal Investigator at Site: UPMC Whitfield Cancer Centre (6 patients involved/116 total – 0,05%)

Years Inclusive: September 2009 – May 2014

Direct Dollars/ Indirecto dollars (total/annual): N/A

Presented in 2015 at Astro Meeting

ICORG 05-03: Prospective Randomised Non-Inferiority Phase 3 Trial Comparing Two Radiation Schedules in Malignant Spinal Cord Compression not Proceeding with Surgical Decompression

All Ireland Cooperative Oncology Research Group, Dublin, Ireland, 2St Luke's Radiation Oncology Network, Dublin, Ireland, 3Galway University Hospital, Galway, Ireland, 4Cork University Hospital, Cork, Ireland, 5Belfast City Hospital, Belfast, United Kingdom, 6Whitfield Clinic, Waterford, Ireland,

Purpose / Objective(s): To prospectively compare two External Beam Radiation Therapy (EBRT) Fractionation Schedules (FS) in patients (pts) with Malignant Spinal Cord Compression (MSCC) not proceeding with surgical decompression.

Materials / Methods: An ICH-GCP compliant prospective (1.1) randomised non-inferiority phase 3 trial compared two EBRT-FS: arm 1 (control): 20 Gy / 5 fractions (#) vs. arm 2 (experimental): 10 Gy / 1 #, with 90% power, 5% significant level and +0.4 noninferiority margin. The primary end-point was the change in mobility at 5 weeks (Modified Tomita score); the secondary end-points were change in bladder function at 5 weeks (in-house score), acute and long-term toxicity (RTOG scale), and overall survival (OS). Eligible pts had pathologically proven metastatic cancer, excluding haematological/ germ cell malignancies, and diagnosed with a MRI documented treatment naïve symptomatic MSCC.

Results: From 2006 to 2014, 5 institutions accrued 116 pts (1 non-eligible pt, no treatment allocation violation), 76 pts alive at 5 weeks were evaluable. The baseline characteristics were balanced between arms [♀/♂ ratio: 36/64, median age: 69 (range: 30-87), median baseline KPS: 60 (range: 30 - 100)]. The main primary tumour sites were prostate (24%), breast (20%) and lung (19%). The MSCC sites were cervical (4.3%), thoracic (67%), lumbar (23.5%), sacral (2.6%) and two synchronous levels (2.6%, 3 pts treated with same FS). Analysis of evaluable pts showed no statistically significant differences in 1) overall mobility score change at 5 week [Overall response (Improvement/Stability) rate: arm 1: 68.4% (10.5/57.9) vs. arm 2: 78.9% (10.5/68.4); mean mobility score change: arm 1: -0.29 vs. arm 2: -0.08, difference= -0.21, 95%CI: -0.56 to 0.14, +0.4 non-inferiority margin outside 95%CI] or 2) bladder function score change at 5 weeks [Overall response (Improvement/stability) rate: arm 1: 75.7% (10.8/ 64.9) vs. arm 2: 86.8% (2.6/84.); mean sphincter score change: arm 1: -0.22 vs arm 2: -0.16, difference = -0.06, 95%CI: -0.44 to 0.32]. The mobility deterioration free survival and overall survival median durations were similar in both arms respectively 1.4 months and 4 months. Independent favourable prognostic factors were 1) for 5 week mobility overall response: preserved baseline mobility, and 2) for OS: preserved baseline mobility, high baseline KPS, young age and non-lung primary. The reported overall toxicity was low with 1 G3- acute and 1 G3-long-term toxicity events (arm 2) and no higher grade toxicity reported.

Conclusions: With respect to mobility preservation, 10 Gy / 1 # is at least equivalent to 20 Gy / 5#. When using EBRT in similar pts, a single fraction schedule should be considered.

 

Source/Grant Number: In-House project in collaboration with Waterford Institute of Technology

Grant Title: Rectal cancer project – early and late toxicity of combined chemo-radiotherapy for rectal cancer patients.

Role in Project & Percentage of Effort: Investigator at Site: UPMC Whitfield Cancer Centre, 100% patients accrued by our Department.

Years Inclusive: 2010 –2014

Direct Dollars (total/annual): N/A

Indirect Dollars (total/annual): N/A

Results of research presented in publications in Clinical Journal of Oncology Nursing and Journal of Clinical Nursing (P. 6)